Pfizer seen as undervalued with strong growth, 6.7% dividend, and improving outlook despite past losses.

Pfizer is currently trading at a low forward earnings multiple of 9.1x and offers a compelling 6.7% dividend yield, making it materially undervalued. The company is facing fewer losses from patent expirations than previously expected, with management now forecasting $14–15 billion in losses, easing long-term revenue concerns. Pfizer's recent product launches and acquisitions are driving strong operational growth of 22%, supported by a robust pipeline especially in oncology and weight loss. The analyst maintains a Buy rating, highlighting Pfizer's recovery signals, strong free cash flow, and focus on business development and dividends, recommending it as an attractive healthcare investment opportunity.